The IL1R1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the interleukin-1 receptor type I (IL1R1) gene. This polyclonal pool contains a heterogeneous collection of edited alleles generated by CRISPR/Cas9-mediated gene disruption, providing a robust model to investigate IL1R1-dependent signaling without the selection of a single clonal phenotype. The product enables systematic analysis of IL-1 pathway biology in a widely used human epithelial tumor background.
HeLa cells are an immortalized epithelial cell line derived from cervical adenocarcinoma and positive for HPV18. This well-characterized model offers a reliable platform for studying cancer biology and signal transduction. The tumorigenic origin and viral oncoprotein expression render HeLa cells pertinent for examining inflammatory signaling contributions to cervical cancer progression.
IL1R1 encodes the primary signaling receptor for the pro-inflammatory cytokines interleukin-1?? (IL-1??) and interleukin-1?? (IL-1??). Ligand binding triggers heterodimerization with the IL-1 receptor accessory protein (IL1RAP), followed by recruitment of the adaptor MyD88 and the kinases IRAK4 and IRAK1. These events promote assembly of a complex that includes TRAF6, leading to TAK1-dependent activation of the IKK?CNF-??B axis and the parallel stimulation of MAP kinases, including JNK and p38. This cascade drives transcription of numerous targets such as IL6, CXCL8, TNF, and PTGS2. The system is modulated by the natural antagonist IL-1RA and the inhibitor Tollip.
In cervical adenocarcinoma, IL-1 signaling contributes to a pro-tumorigenic inflammatory milieu, influencing processes like proliferation, migration, and matrix metalloproteinase expression. HeLa cells harbor HPV18 oncoproteins that intersect with host inflammatory pathways; therefore, IL1R1 knockout permits clear dissection of direct tumor-cell responses to IL-1. This facilitates identification of cancer cell-intrinsic vulnerabilities within the pathway.
This polyclonal knockout model supports diverse applications, including mechanistic studies of IL-1 signaling in cancer, functional genomics, and drug discovery targeting the IL1R1?CIL1RAP?CMyD88?CIRAK4 axis. Downstream activation can be assessed by western blotting for NF-??B and MAPK phosphorylation, RT-qPCR quantification of IL6 and CXCL8, or ELISA measurement of secreted IL-6 and IL-8. Phenotypic assays for proliferation and migration can be combined with NF-??B luciferase reporter systems to evaluate pharmacological inhibitors. The model is especially suited for screening small molecules against key signaling nodes. For additional protocol details or technical support, please contact Ascent Research.
